GlassScriptPhysician profile
Wesley Drew Chapman
NPI 1477846707
$8,165.57
in general payments reported to CMS, 2019-2025
24 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what 86% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,746 · 2020: $490 · 2021: $799 · 2022: $1,671 · 2023: $352 · 2024: $807 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Travel and Lodging: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.98 |
| Travel and Lodging | $1,238.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,661.88 | 2019-2025 | |
| Orthofix Medical, INC. | $1,820.82 | 2019-2025 | Truelok, Physio-Stim |
| Organogenesis INC. | $1,439.55 | 2019-2022 | |
| Aroa Biosurgery Incorporated | $445.43 | 2024 | |
| Paratek Pharmaceuticals, INC. | $271.80 | 2023-2025 | Nuzyra |
| Wright Medical Technology, INC. | $256.30 | 2019-2020 | |
| Djo, LLC | $215.47 | 2019-2025 | Cmf |
| Acera Surgical, INC. | $146.57 | 2024 | Restrata Wound Matrix |
| Smith+Nephew, INC. | $132.82 | 2021-2025 | Collagenase Santyl |
| Biocomposites INC | $121.92 | 2019-2025 | Stimulan |
| Stryker Corporation | $118.50 | 2021 | |
| Kci USA, INC. | $115.53 | 2021 | |
| Depuy Synthes Sales INC. | $112.56 | 2023-2025 | Hammerlock, Na, Motoband |
| Treace Medical Concepts, INC. | $93.25 | 2024-2025 | |
| Reprise Biomedical, INC. | $33.40 | 2023 | Miro3d |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $25.50 | 2019 | |
| Zimmer Biomet Holdings, INC. | $23.43 | 2019 | |
| Ibsa Pharma INC. | $22.51 | 2023 | Tirosint, Licart |
| Triad Life Sciences INC. | $22.00 | 2022 | |
| Mimedx Group, INC. | $20.88 | 2024 | |
| Horizon Therapeutics Plc | $20.06 | 2023 | Krystexxa |
| Carbofix Orthopedics INC | $17.15 | 2023 | |
| Arteriocyte Medical Systems, INC. | $16.02 | 2024 | Magellan |
| Dynasplint Systems INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.